Mercer Convertible Securities Conversion and Amendment
Filed with ASX · · 2 pages · English
Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging technology, is pleased to inform shareholders of the following updates related to the Convertible Securities Agreement entered into with Mercer Street Global Opportunity Fund, LLC (Mercer Street) dated on or about
Imagion Biosystems Ltd. on 6ix
Earlier from Imagion Biosystems
- Positive Final WSU Trial Results To Support IND Submission
- Positive Results Received from WSU on MagSense Dosage
- Appendix 4C and Quarterly Activities Report - September 2025
- Imagion Biosystems HER2 Breast Cancer Program Update
- Ph2 Manufacturing & Imaging Optimisation Activities Commence
Later from Imagion Biosystems
- Appendix 4C and Quarterly Activities Report - December 2025
- IBX's IND Application Lodged with FDA for HER2 Phase 2 Trial
- Medical-imaging company Imagion Biosystems Lodges IND with FDA for Phase 2 Trial of MagSense® HER2 targeted imaging agent
- FY25 Appendix 4E and Annual Report
- Appendix 4C and Quarterly Activities Report - March 2026
Follow Imagion Biosystems into a list and get an email when it puts out news.
Follow Imagion Biosystems